Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Atara Biotherap (ATRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Watch for Atara Biotherape to Potentially Rebound After Falling 1.21% Yesterday

Atara Biotherape (NASDAQ:ATRA) traded in a range yesterday that spanned from a low of $39.26 to a high of $41.95. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of...

ATRA : 39.20 (-0.25%)
Atara Biotherapeutics Opens State-of-the-Art Operations and Manufacturing Facility to Support Robust Off-the-Shelf T-Cell Immunotherapy Pipeline

Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced...

ATRA : 39.20 (-0.25%)
Atara Biotherapeutics' Tab-cel(TM) Achieves Positive Long-Term Outcomes in Phase 2 Studies of Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas

Findings presented at 23rd Congress of European Hematology Association

ATRA : 39.20 (-0.25%)
Atara Biotherapeutics Announces Publication of New Research Linking Epstein-Barr Virus (EBV) Infection and Multiple Sclerosis (MS)

Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced...

ATRA : 39.20 (-0.25%)
Free Technical Reports on Arrowhead Pharma and Three Additional Biotech Equities

Stock Research Monitor: ATRA, ATHX, and EARS

ARWR : 16.03 (-1.72%)
ATRA : 39.20 (-0.25%)
ATHX : 2.07 (unch)
T2 Biosystems is Among the Companies in the Biotechnology Industry with the Best Relative Performance (TTOO, ATRA , ICPT , ADRO , FGEN )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

TTOO : 6.63 (-3.91%)
ATRA : 39.20 (-0.25%)
ICPT : 93.80 (-2.02%)
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported...

ATRA : 39.20 (-0.25%)
Atara Biotherapeutics Announces Appointment of Utpal Koppikar as Chief Financial Officer

Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced...

ATRA : 39.20 (-0.25%)
Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences

Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced...

ATRA : 39.20 (-0.25%)
Biotech Market Value Set to Grow Due to Technological Advancements

According to a report by Global Market Insights, Inc., the Biotechnology Market size is projected to reach USD 775.2 billion with 9.9% CAGR by 2024. Based on technology, the industry is segmented into...

SGMO : 15.10 (+0.33%)
ATRA : 39.20 (-0.25%)
VCEL : 10.60 (+1.92%)
ATHX : 2.07 (unch)
AVCO : 2.8000 (unch)
SmarTrend Watching for Potential Pullback in Shares of Atara Biotherape After 4.59% Gain

Atara Biotherape (NASDAQ:ATRA) traded in a range yesterday that spanned from a low of $47.80 to a high of $50.85. Yesterday, the shares gained 4.6%, which took the trading range above the 3-day high...

ATRA : 39.20 (-0.25%)
Atara Biotherapeutics to Present Long-Term Tab-cel(TM) Phase 2 Clinical Outcomes for Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas at 23rd Congress of European Hematology Association

Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced...

ATRA : 39.20 (-0.25%)
Atara Biotherape Rises 3.65% on Heavy Volume: Watch For Potential Pullback

Atara Biotherape (NASDAQ:ATRA) traded in a range yesterday that spanned from a low of $40.00 to a high of $42.40. Yesterday, the shares gained 3.7%, which took the trading range above the 3-day high...

ATRA : 39.20 (-0.25%)
Wired News - Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration with MSK to Develop Next-Generation CAR T Technologies

Stock Monitor: Cellectis Post Earnings Reporting

CMVLF : 30.0000 (-2.91%)
ATRA : 39.20 (-0.25%)
Atara Biotherapeutics Announces First Quarter 2018 Financial Results and Recent Operational Progress

Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported...

ATRA : 39.20 (-0.25%)
Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration to Advance Next-Generation CAR T Technologies in Oncology, Autoimmune and Other Diseases

Entry into genetically engineered T-cells marks next step in Atara's strategy to advance leadership position in off-the-shelf, allogeneic T-cell immunotherapy

ATRA : 39.20 (-0.25%)
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported...

ATRA : 39.20 (-0.25%)
Biotech Industry Veteran Dietmar Berger, M.D., Ph.D., Joins Atara Biotherapeutics as Global Head of Research and Development

Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced...

ATRA : 39.20 (-0.25%)
Atara Biotherapeutics Expands Commercial Leadership Team with the Appointment of Manuela Maronati as General Manager, Europe

Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced...

ATRA : 39.20 (-0.25%)
Relatively Good Performance Detected in Shares of Atara Biotherape in the Biotechnology Industry (ATRA , EPZM , SAGE , LOXO , ONCE )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

SAGE : 168.56 (-0.04%)
ATRA : 39.20 (-0.25%)
EPZM : 13.40 (-1.11%)

Van Meerten Stock Picks

5 Terrific Mid Caps
In this roller coaster market I wanted to find Mid Cap stocks that had consistent price appreciation over the last 6 month period.
EHC -0.38 , FTNT +0.53 , CAKE -0.45 , PLT -0.28 , AEO -0.65
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Agricharts Market Commentary

Today's Commentary

Corn futures closed the week with most contracts 3 to 4 cents higher on Friday. Nearby September was up 4.1% since last Friday, with higher closes every day this week. Solid exports and drier weather fueled some bottom picking and short covering acti...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar